Anzeige
❌
Mehr »
Login
Dienstag, 04.03.2025 Börsentäglich über 12.000 News von 689 internationalen Medien
Eilmeldung: Trumps Krypto-Reserve löst Markt-Explosion aus - Pioneer AI Foundry setzt auf Solana!
Anzeige

Indizes
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Aktien
Kurs
%		News
24 h / 7 T		Aufrufe
7 Tage

Xetra-Orderbuch

Fonds
Kurs
%

Devisen
Kurs
%

Rohstoffe
Kurs
%

Themen
Kurs
%

Erweiterte Suche

WKN: A2PSSH | ISIN: US45781K2042 | Ticker-Symbol: IDDA
Siehe auch INNATE PHARMA SA
Frankfurt
04.03.25
09:59 Uhr
1,940 Euro
-0,080
-3,96 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INNATE PHARMA SA ADR Chart 1 Jahr
5-Tage-Chart
INNATE PHARMA SA ADR 5-Tage-Chart

Aktuelle News zur INNATE PHARMA SA ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoInnate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
DoInnate Pharma SA: Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference192Business WireRegulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of its executive team will present and host 1x1 meetings at the Leerink...
► Artikel lesen
18.02.Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments1Seeking Alpha
18.02.Innate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
17.02.Innate Pharma: FDA Grants Breakthrough Therapy Designation To Lacutamab For R/R Sezary Syndrome8RTTNews
17.02.Innate Pharma SA: Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome340Business WireDesignation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable safety profile in patients with advanced Sézary syndrome heavily pre-treated, post- mogamulizumab. ...
► Artikel lesen
27.01.Innate Pharma SA: Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors241Business WireIPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4 Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate"...
► Artikel lesen
INNATE PHARMA SA ADR Aktie jetzt für 0€ handeln
21.01.Innate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
21.01.Innate Pharma SA: Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York229Business WireInnate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate"...
► Artikel lesen
21.01.Innate Pharma SA: Innate Pharma Announces Nectin-4 Antibody Drug Conjugate Investor and Analyst Event in New York320Business WireInnate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate"...
► Artikel lesen
16.01.Innate Pharma SA: Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024335Business WireRegulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General...
► Artikel lesen
10.01.Innate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
10.01.Innate Pharma SA: Innate Pharma Announces Transformative Strategy to Accelerate Growth343Business WireStrategy anchored on early clinical development of proprietary assets with single-agent potential: Drive innovation with first-in-class ANKET NK-cell engager Platform Accelerate...
► Artikel lesen
20.12.24Innate Pharma SA - 6-K, Report of foreign issuer1SEC Filings
20.12.24Innate Pharma SA: Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference272Business WireRegulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that its management will present and host 1x1 meetings at the 43rd Annual J.P....
► Artikel lesen
09.12.24Innate Pharma presents lacutamab improved health-related quality of life data at ASH 202411Seeking Alpha
09.12.24Innate Pharma SA: Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma389Business WireFindings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas Regulatory News: Innate Pharma SA (Euronext Paris:...
► Artikel lesen
06.12.24Innate Pharma SA: Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma437Business WireInnate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma...
► Artikel lesen
03.12.24Innate Pharma SA - 6-K, Report of foreign issuer-SEC Filings
03.12.24Innate Pharma SA: Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024404Business WireRegulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that abstracts related to lacutamab health-related quality of life and translational...
► Artikel lesen
Seite:  1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1